US jury says Bayer must pay US$81 million to man in Roundup cancer trial

Singapore News News

US jury says Bayer must pay US$81 million to man in Roundup cancer trial
Singapore Latest News,Singapore Headlines
  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 66%

US jury hits Bayer with US$81 million in Roundup cancer trial

SAN FRANCISCO: A U.S. jury on Wednesday awarded US$81 million to a man who claimed his use of Bayer AG's glyphosate-based weed killer Roundup caused his cancer, in the latest legal setback for the company facing thousands of similar lawsuits.

The jury in San Francisco federal court said the company was liable for plaintiff Edwin Hardeman's non-Hodgkin's lymphoma.It awarded US$5.9 million in compensatory and US$75 million in punitive damages to Hardeman after finding that Roundup was defectively designed, that Monsanto failed to warn of the herbicide's cancer risk and that the company acted negligently.

The trial is only the second of more than 11,200 Roundup lawsuits set to go to trial in the United States. Previous litigation setbacks and a prior jury verdict against the company have sent Bayer shares plunging.The verdict comes roughly a week after the same jury on March 19 found Roundup to have been a"substantial factor" in causing Hardeman's cancer, allowing the trial to proceed into a second phase to determine liability and damages.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

ChannelNewsAsia /  🏆 6. in SG

Singapore Latest News, Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Bayer, J&J settle US Xarelto litigation for US$775 millionBayer, J&J settle US Xarelto litigation for US$775 millionBayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of ...
Read more »

Europe: Stocks break 5-day rally; Bayer, BMW weigh on DAXEurope: Stocks break 5-day rally; Bayer, BMW weigh on DAX[BENGALURU] European shares retreated from near six-month highs on Wednesday, with German stocks leading losses as chemicals producer Bayer and carmaker BMW tumbled, and as the European Union resisted British Prime Minister Theresa May's plea to delay Brexit. Read more at The Business Times.
Read more »

Bayer CEO says his team retains backing of supervisory board: reportBayer CEO says his team retains backing of supervisory board: reportBayer's management retains the backing of its supervisory board, its chief executive said, after pressure on the company increased when a second ...
Read more »

Bayer, J&J settle US Xarelto litigation for US$775 millionBayer, J&J settle US Xarelto litigation for US$775 millionBayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of ...
Read more »

New Jersey jury clears J&J of liability in latest talc cancer trialNew Jersey jury clears J&J of liability in latest talc cancer trialA New Jersey jury has cleared Johnson & Johnson of liability in a lawsuit by a man who alleged the company's talc-based products, including baby ...
Read more »

Deutsche Bank CEO paid US$8 million, top managers get first bonuses in four yearsDeutsche Bank CEO paid US$8 million, top managers get first bonuses in four yearsDeutsche Bank paid its management board members their first bonuses in four years in 2018, with Christian Sewing's 7 million euro (US$8 million) ...
Read more »

Biogen scraps Alzheimer drug trials, wiping US$17 billion off its market valueBiogen scraps Alzheimer drug trials, wiping US$17 billion off its market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Read more »

Biogen announces US$5 billion buyback days after shelving Alzheimer's trialsBiogen announces US$5 billion buyback days after shelving Alzheimer's trialsBiogen Inc said on Monday it would buy back shares worth US$5 billion, days after its stock slumped on the drugmaker's announcement to end two ...
Read more »

Biogen scraps two Alzheimer drug trials, wipes US$18 billion from market valueBiogen scraps two Alzheimer drug trials, wipes US$18 billion from market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Read more »



Render Time: 2025-04-07 10:04:30